logo
Share SHARE
FONT-SIZE Plus   Neg

Proofpoint Prices IPO At $13/Share, Above Estimated Range

Proofpoint Inc. (PFPT), a pioneering provider of cloud-based security and compliance solutions for enterprise messaging and collaboration, announced the pricing of initial public offering of 6.33 million shares of its common stock at $13.00 per share, above its estimated offering price range.

Of the shares of common stock in the offering, Proofpoint is offering 5.13 million shares of common stock and selling stockholders are offering 1.2 million shares of common stock.

In an amended regulatory filing with the U.S. Securities and Exchange Commission on April 9, the company had expected to price the initial public offering of 6.2 million common shares between $10 and $12 per share.

Sunnyvale, California based company shares are expected to begin trading on The Nasdaq Global Market on April 20, 2012 under the symbol "PFPT."

In addition, Proofpoint and the selling stockholders have granted the underwriters a 30-day option to buy up to 770 thousand additional shares of common stock to cover over-allotments, if any.

Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. are serving as joint book runners for the offering. RBC Capital Markets LLC, Pacific Crest Securities LLC and First Analysis Securities Corp. are acting as co-managers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Fast food giant McDonald's on Wednesday announced its global growth plan, targeting sales growth of 3-5% beginning in 2019. The company also highlighted its vision for new restaurants relying on technology such as self-ordering kiosks, curbside pick ups and partnerships with delivery services. At... Canadian drug-maker Valeant Pharmaceuticals International, Inc. on Tuesday reported a loss for the fourth quarter that widened from last year on a double-digit decline in revenues. However, both revenue and adjusted earnings beat analysts' estimates. Valeant also said it plans to relaunch its sexual dysfunction drug Addyi in the U.S. Electronics retailer Best Buy Co., Inc. Wednesday issued guidance for first-quarter adjusted earnings and revenues, below market estimates. Comparable sales are expected to be weak. For fiscal 2018, the company projects higher revenues and operating income. In its fourth quarter, the company posted higher profit, above market view, while revenues missed estimates with lower comparable sales.
comments powered by Disqus
Follow RTT